GLOFITAMAB

2709 reported adverse events

Drug classes: Bispecific CD20-directed CD3 T Cell Engager [EPC]

These side effects are most commonly reported by patients taking GLOFITAMAB:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 855
1 DISEASE PROGRESSION 486
2 OFF LABEL USE 325
3 DEATH 304
4 PYREXIA 221
5 NEUTROPENIA 198
6 IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME 156
7 COVID-19 126
8 ANAEMIA 115
9 INFECTION 114
See all common reactions for GLOFITAMAB

GLOFITAMAB is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HIGH GRADE B-CELL LYMPHOMA BURKITT-LIKE LYMPHOMA REFRACTORY 4 0.8000
1 HERPETIC RADICULOPATHY 1 0.1250
2 PRIMARY CARDIAC LYMPHOMA 2 0.1250
3 BLOOD TYPE INCOMPATIBILITY 1 0.1250
4 HEPATOBILIARY NEOPLASM 1 0.1000
5 EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE) STAGE IV 1 0.0833
6 TUMOUR FLARE 56 0.0820
7 CD19 ANTIGEN LOSS 1 0.0625
8 INTERSTITIAL LUNG THICKENING 1 0.0625
9 FACTOR XI DEFICIENCY 1 0.0500
See all enriched reactions for GLOFITAMAB